Balaglitazone

Summary

Balaglitazone (CHEMBL2103991) is a phase-3 clinical-stage small molecule; indicated across 1 condition including type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 395.4 Da · C20H17N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2103991
Name	Balaglitazone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9889200
Molecular formula	C20H17N3O4S
Molecular weight	395.4
InChIKey	IETKPTYAGKZLKY-UHFFFAOYSA-N

SMILES: CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4

IUPAC name: 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Also known as: Balaglitazona, Balaglitazone, Drf-2593, DRF-2593, NN-2344, BALAGLITAZONE

Patent coverage: 536 distinct patent families (1,485 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,020 (69%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Peroxisome proliferator-activated receptor gamma.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPARG	5.87	EC50	1350	nM	CHEMBL_ACT_29256504

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00515632	PHASE3	COMPLETED	Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).